NEW ORLEANS, March 26, 2007 /PRNewswire/ -- A large patient
registry of "real world" uses for the CYPHER(R) Sirolimus-eluting
Coronary Stent reported favorable safety and efficacy outcomes at
two-year follow-up, according to clinical investigators at the of
Cardiology's 56th Annual Scientific Session (ACC.07).

The MATRIX Registry is a prospective, single-arm study designed
to evaluate the outcomes of percutaneous coronary intervention (PCI
or balloon angioplasty) with the CYPHER(R) Stent in everyday
medical practice out to five years. Sponsored by Cordis
Corporation, the registry reports on clinical data from 1,522
consecutive patients in whom the CYPHER(R) Stent was implanted,
including high percentages of complex patient populations that are
not currently within the approved labeling, such as patients with
diabetes (33.8 percent), or history of heart attack (33.4 percent),
balloon angioplasty (44.6 percent) or bypass surgery (21 percent).
Overall, 86 percent of the interventions involved a specific
patient or lesion characteristic not currently within the approved
labeling for the CYPHER(R) Stent, and would be considered
"off-label."

"The MATRIX Registry provides invaluable information to help
physicians assess the long-term safety of the CYPHER(R) Stent in
'real world' patient populations," said Principal Investigator
George D. Dangas, M.D., Ph.D., Associate Professor of Medicine, The
Cardiovascular Research Foundation/Columbia University Medical
Center, who presented the results.

In spite of the overall patient and lesion complexity, the
MATRIX Registry indicated low frequency of adverse events with the
CYPHER(R) Stent throughout the two years of patient follow-up.
Applying the Academic Research Consortium (ARC) definition of stent
thrombosis, the investigators reported a 0.7 percent rate of
definite stent thrombosis and a 1.1 percent rate of
definite/probable stent thrombosis. Total mo
rtality and cardiac
mortality was 3.3 percent and 1 percent, respectively. In addition,
the rate for myocardial infarction (heart attack) was 4 percent,
and the percentage of patients who required a second procedure to
reopen the treated artery (target vessel revascularization or TVR)
was 10.7 percent. These rates are comparable to the incidences
found for the CYPHER(R) Stent in the randomized clinical trials
that led to its regulatory approval in the United States.

"While randomized clinical trials offer the highest level of
evidence, registries such as MATRIX play an important role in
generating hypotheses and helping to monitor the outcomes of
breakthrough therapies like the CYPHER(R) Stent in current clinical
practice," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I.,
Chief Medical Officer, Cordis Cardiology Division, Cordis
Corporation. "The MATRIX Registry adds to the growing body of
evidence assessing the CYPHER(R) Stent, the most studied medical
device in history, in complex patient populations."

The MATRIX Registry also showed no stent thrombosis or mortality
differences between the off-label complex patient subgroups and the
patient subgroups indicated to receive the CYPHER(R) Stent in the
United States. In the off-label patient subgroup, the MATRIX
Registry investigators reported a definite/probable stent
thrombosis incidence of 1.1 percent, which was not statistically
different from the 0.5 percent rate found in on-label patients
(p=0.649). Likewise, the mortality rate for the off-label patients
was 3.4 percent, which was not statistically different from the 2.7
percent rate in the on-label subgroup (p=0.519).

Dr. Dangas noted that the MATRIX Registry also found
significantly higher rates of myocardial infarction or target
vessel revascularization (TVR) in the complex patient subgroup
compared to the rates seen in the on-label patient population. The
myorcardial infarction rate for on-label patients was 0.9 percent
versus 4.4 perc
ent in the off-label patient arm (p=0.048). The TVR
rate for on-label patients was 4.5 percent versus 11.6 percent in
the off- label patient arm (p=0.040). "These findings are
consistent with the overall clinical evidence, which shows complex
patients to have higher event rates based on their complexity," he
said.

The MATRIX Registry also tracked patient outcomes with dual
anti-platelet therapy. According to the results, 75 percent of the
patients included in the registry adhered to a prescribed dual
antiplatelet therapy out to one year. However, such compliance did
not result in significant differences in the rates of mortality,
heart attack or stent thrombosis after one year compared to the
outcomes of patients who stopped dual anti-platelet therapy before
one year.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide
to treat approximately three million patients with coronary artery
disease. The safety and efficacy of the device is supported by a
robust clinical trial program that includes more than 70 studies
that examine the performance of the CYPHER(R) Stent in a broad
range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R)
Stent is currently available in more than 80 countries and has the
broadest clinical experience and longest-term clinical follow-up of
any drug-eluting stent. The next version of sirolimus-eluting
stent, the CYPHER(R) SELECT(TM) Sirolimus-eluting Coronary Stent,
was launched in Europe, Asia Pacific, Latin America and Canada in
2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a
sirolimus-eluting coronary stent, received CE Mark in 2006 and is
currently available in many markets outside the United States.

For more complete information on indications, contraindications,
warnings and precautions, see the Instructions for Use available at
www.cypherstent.com.

About Cord
is Corporation

Cordis Corporation, a Johnson & Johnson company, is a
worldwide leader in the development and manufacture of
interventional vascular technology. Through the company's
innovation, research and development, Cordis partners with
interventional cardiologists worldwide to treat millions of
patients who suffer from vascular disease. More information about
Cordis Corporation can be found at www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with
Wyeth for the localized delivery of sirolimus in certain fields of use,
including delivery via vascular stenting. Sirolimus, the active drug
released for the stent, is marketed by Wyeth Pharmaceuticals, a division
of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth
Pharmaceuticals.

(Date:10/7/2017)... 2017 Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...

(Date:10/4/2017)... Oct. 4, 2017 According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...

(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...

(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...

(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...

(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...

(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...